Clinical trial · Observational
The Rechallenge of ADCs in MBC Patients
A Multicenter, Real-world Study of the Efficacy and Safety of Antibody-drug Conjugates (ADCs) Rechallenge in Patients with Prior Exposure to ADCs Metastatic Breast Cancer
NCT05571618CI-TRIAL-00081776active not recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To investigate the efficacy and safety of ADC rechallenge
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ADC | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Group1
- interventionNames
- Drug: ADC
Primary outcomes (1)
- measure
- PFS
- timeFrame
- 6 weeks
- description
- Progression free survival
Secondary outcomes (5)
- measure
- ORR
- timeFrame
- 6 weeks
- description
- Objective Response Rate
- measure
- CBR
- timeFrame
- 6 weeks
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * age \> 18 years old. * Diagnosed with Metastatic Breast Cancer. * Patients with prior exposure to ADC (either in the adjuvant setting or metastatic disease are allowed). * Patients plan to or have received ADCs for the second or more time. * Complete medical history was available. Exclusion Criteria: * Medical history was incomplete
References
Publications (0)
Data not yet available
No reference posted for this study.